VIRTUAL EXHIBIT HALL

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
8d24929b0ebd57e691ea9db331e1c1fa-youtube
8d24929b0ebd57e691ea9db331e1c1fa-youtube

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG).

For more information about Alexion, visit alexion.com.

Arbor Pharmaceuticals is led by a team of skilled pharmaceutical veterans, many of whom have experience as healthcare practitioners. Our people fully understand the pharmaceutical development process and value our products can bring to the lives of patients. The Arbor team is now over 300 strong and has full knowledge and capabilities in pharmaceutical research and development, manufacturing, quality control and market commercialization. We work with numerous partners throughout the world for the licensing, manufacturing or development of our marketed and late stage pipeline products.

Arbor Pharmaceuticals has established the goal of becoming the largest privately owned U.S. pharmaceutical company. We are currently working with many of the local universities and discovery centers to identify and keep those innovations in the Atlanta economy through partnerships with Arbor. Our focus is on identifying opportunities that offer improved outcomes for our patients.

For more information, visit arborpharma.com.

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technologies to create new and potentially best-in-class therapies.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs.

Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, and in Palo Alto and Redwood City, California.

For more information, please visit www.ascendispharma.com.

Or, email Ascendis Pharma, Inc. at medicalinformation@ascendispharma.com

At Endo International, our generics and specialty branded products play an important role in helping millions of patients lead healthier lives.

 

Through our operating companies, we are dedicated to delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization.

For more information about Endo, visit endo.com.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.

 

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. 

For more information about Pfizer, please visit:

pfizer. com

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

 

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

 

For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.

Human Growth
Foundation

Headquarters:

997 Glen Cove Ave, Suite 5

Glen Head, New York 11545 USA

Email: hgf1@hgfound.org

Telephone: 1-800-451-6434

Fax Number: 1-516-671-4055

Human Growth Foundation (HGF)

is a  501(c)(3) non-profit organization.

 

Federal Tax Identification# 16-0913012  

Get HGF Updates

© 2020 by Human Growth Foundation. Created by D. Plump Consulting